Filing Flows › Enanta Pharmaceuticals (ENTA) › Q3 FY25
Enanta Pharmaceuticals (ENTA) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Aug 13, 2025
Enanta Pharmaceuticals (ENTA) reported revenue of $18.3M for the third quarter fiscal 2025 (Q3 FY25), +2% from a year earlier and +23% from the quarter before. Operating margin was -103.2%, net loss $18.3M (99.7% of revenue).
Enanta Pharmaceuticals, Q3 FY25: revenue $18.3M (+2% year over year), operating margin -103.2%, net loss $18.3M, operating cash flow $17.5M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.3M | +23% | +2% |
| Operating profit | −$18.9M | — | — |
| Net earnings | −$18.3M | — | — |
| Operating cash flow | $17.5M | — | — |
| Free cash flow | $17.4M | — | — |
What changed
Revenue was $18.3M in Q3 FY25, up 2% year over year and up 23% from the previous quarter.
Operating costs exceeded revenue by $18.9M, an operating margin of -103.2%. Total costs fell 12% while revenue rose 2%. The quarter ended with a net loss of $18.3M, narrower than the previous quarter's $22.6M loss.
Operating cash flow was $17.5M. Non-cash charges added back $1.2M of depreciation and amortization and $4.2M of share-based compensation. Working capital and other items added $30.4M. Capital expenditures of $155K left free cash flow of $17.4M.
Questions
What was Enanta Pharmaceuticals' revenue in the third quarter fiscal 2025?
Enanta Pharmaceuticals (ENTA) reported revenue of $18.3M for the third quarter fiscal 2025 (Q3 FY25), +2% from a year earlier and +23% from the quarter before.
Was Enanta Pharmaceuticals profitable in the third quarter fiscal 2025?
Operating loss was $18.9M (-103.2% of revenue) and net loss $18.3M.